Preemptive treatment based on the sensitive detection of CMV-DNA has helped to reduce HCMV-related mortality after allogeneic stem cell transplantation (SCT). Detection of active viral replication might help to better predict HCMV disease. In this study, 33 recipients at risk for HCMV infection after allogeneic SCT were prospectively monitored 1؋/week for active HCMV infection by NASBA, whole blood DNA-PCR and virus culture assays. Preemptive antiviral therapy was initiated after the second positive PCR result, while NASBA results were not considered for clinical decision-making. Overall, a high agreement between PCR and NASBA on a per sample (85.3%) and per patient (87.9%) level was demonstrated. HCMV DNA titers in the blood were found to be higher in PCR + /NASBA + compared to PCR + /NASBA ؊ samples (P Ͻ 0.01). None of the NASBA-negative patients developed HCMV disease. Sixteen of 18 patients receiving PCR-based preemptive therapy were also found NASBA positive. There was no difference between the assays for the time to the first positive test result. However, the time to the first negative test result upon initiation of antiviral therapy was significantly shorter for the NASBA assay (P ‫؍‬ 0.002), indicating a high positive predictive value to assess the efficacy of antiviral therapy. Three patients developed late-onset HCMV disease, all of whom were found to be PCR and NASBA positive. In conclusion, the data presented clearly demonstrate the value of patient monitoring using the NASBA assay to early diagnose active HCMV infection and to assess the efficacy of antiviral therapy in high risk patients after allogeneic SCT. A prospective comparison of PCR-based vs NASBAbased preemptive therapy is ongoing.
Human cytomegalovirus (HCMV) infection remains a major cause of morbidity and mortality in patients after allogeneic stem cell transplantation (SCT). [1] [2] [3] [4] Prophylactic and preemptive antiviral therapy based on home-made PCR and pp65 antigenemia assays have been shown to significantly reduce HCMV disease and HCMV-associated mortality following allogeneic SCT in the early post-transplant period. [5] [6] [7] [8] [9] [10] As a consequence of the broad application of antiviral drugs prior to day 100 post transplantation, HCMV disease occurring after day 100 post transplantation now represents one of the leading causes of mortality after allogeneic SCT. 5, 11 In a recent analysis, antiviral therapy of more than 4 weeks prior to day 100, acute graft-versus-host disease and corticosteroid treatment were the most important risk factors for late HCMV disease in a cohort of patients receiving PCR-based antiviral therapy. 11 In line with these results, antiviral prophylaxis with ganciclovir given at engraftment until day 100 post transplantation has been found to delay the development of HCMV-specific cytotoxic T lymphocytes leading to late-stage interstititial pneumonia after cessation of drug treatment. 12 As only about 30% of the patients at risk will develop HCMV disease, overtreatment in patients receiving antiviral prophylaxis is approximately 70%, while approximately 50% of patients receiving PCR-or antigenemia-based preemptive therapy are overtreated.
In contrast to the detection of HCMV-DNA by qualitative in-house PCR assays or commercially available quantitative PCR tests, [13] [14] [15] the detection of HCMV-specific mRNA more directly reflects active viral gene expression and replication in clinical specimens. 16 Moreover, analysis of late genes expressed only during a complete replication cycle of HCMV might allow the restriction of antiviral therapy to patients suffering from productive disseminating HCMV infection. Recently, an internally controlled and standardized assay for the detection of HCMV pp67 (UL65) messenger RNA, a true late gene product of HCMV, has been commercialized (NucliSens CMV pp67; Organon Teknika, The Netherlands). The assay is based on the isothermal amplification by nucleic acid sequence-based amplification (NASBA) 17 and does not use temperatures that would allow amplification of HCMV DNA.
In this study, the NASBA assay was compared to a home-made PCR assay 18 for its potential to diagnose
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HCMV infection early after allogeneic SCT and to monitor the efficacy of antiviral treatment.
Materials and methods

Patients
Thirty-three patients at risk of developing HCMV infection after allogeneic stem cell transplant were studied between May 1998 and March 1999. Patients were either monitored from the time of transplant until day 100 (n ϭ 28) or thereafter (n ϭ 5) if considered to be at high risk for HCMV infection and disease from intensive immunosuppressive therapy. All 33 recipients of an allogeneic SCT were monitored weekly for signs of active HCMV infection by NASBA, PCR from whole blood, and conventional as well as rapid virus culture assays from blood, urine and throat wash samples. The median age was 42 (range 2-53) years. Twelve of 33 patients received a transplant from an unrelated donor, and three from an HLA-mismatched family donor. Sixteen patients received allogeneic stem cells from the bone marrow and 17 from mobilized peripheral blood. Twenty patients received a conditioning regimen containing fractionated total body irradiation (3ϫ 2ϫ 2 Gy) and 13 patients were treated with a busulfan-based myelo-ablative chemotherapy regimen. Patient characteristics at the time of transplant are shown in Table 1 . Oral acyclovir was administered in all patients at 4ϫ 400 mg/day for prophylaxis of herpes simplex virus infection. In addition to these study patients, 20 samples from 18 HCMV-seronegative patients transplanted from a seronegative donor were included as negative controls. All HCMV-seropositive patients and/or those receiving a transplant from an HCMV-seropositive donor received blood products unscreened for HCMV.
Therapy for HCMV infection and disease
All patients after allogeneic SCT received PCR-based preemptive therapy. NASBA was not considered for clinical decision-making. PCR-based preemptive therapy with ganciclovir (dosage 2 ϫ 5 mg/kg body weight/day) or foscarnet (dosage 2 ϫ 60 mg/kg body weight/day) was initiated after the second consecutive positive PCR result as previously described. 8 Patients with documented HCMV disease received combination therapy with ganciclovir and HCMV-hyperimmunoglobulin. To reduce the duration of antiviral therapy, antiviral therapy was stopped after 14 days if clearance of the virus could be documented by PCR. Thus, maintenance therapy with ganciclovir 6 mg/kg/day 5 ϫ weekly or foscarnet 90 mg/kg/day 5 ϫ weekly was only administered when PCR remained positive after a 14-day course of antiviral therapy.
Definitions of HCMV infection and disease
All patients testing positive by the in-house PCR method were considered to be actively HCMV infected.
HCMV disease was diagnosed according to the criteria defined by the Fourth International Cytomegalovirus Workshop in Paris 1993, 19 as follows: HCMV pneumonia: dyspnea, interstitial infiltrates on the chest radiograph, positive HCMV culture of bronchial washings; HCMV enteritis: gastrointestinal symptoms, demonstration of HCMV by histology or immunohistology; HCMV hepatitis: abnormal liver function, typical histological changes and detection of HCMV in the liver biopsy by culture or DNA hybridization.
Nucleic acid sequence-based amplification (NASBA)
The NASBA assay was carried out according to the manufacturer's instructions (Organon Teknika, Boxtel, The Netherlands). Briefly, 0.1 ml of heparinized or EDTAanticoagulated blood was mixed thoroughly with 0.9 ml of NASBA lysis buffer (4.7 m guanidinium thiocyanate, 46 mm Tris (pH 6.4), 20 mm EDTA, 1.2% (wt/vol) Triton X-100), and the mixture was stored at 70ºC. A standardized amount of system control (SC) RNA, which served as a positive control for the isolation, amplification, and detection of RNA during the assay procedure, was added prior to silica-based nucleic acid isolation, 20 which was performed essentially as described by Boom et al. 21 The nucleic acids were finally eluted in 50 l of 1.0 mm Tris (pH 8.5). The NASBA amplification reaction was performed with two primers, which were designed to amplify part of the mRNA encoding HCMV pp67 (the UL 65 gene product). NASBA reactions were carried out as described by Kievits et al 17 in a 20 l reaction mixture containing 40 mm Tris (pH 8.5), 12 mm MgCl 2 , 70 mm KCl, 15% (vol/vol) dimethyl sulfoxide, 5 mm dithiothreitol, each deoxynucleoside triphosphate at a concentration of 1 mm, ATP, CTP and UTP each at a concentration of 2 mm, 1.5 mm GTP, 0.5 mm ITP, 2 g of bovine serum albumin, 0.08 U of RNase H, 32 U of T7 RNA polymerase, 6.4 U of avian myeloblastosis reverse transcriptase, each primer at a concentration of 0.2 m, and 5 l of isolated nucleic acids. Prior to the addition of the enzymes, the NASBA reaction mixtures were incubated for 5 min at 65ºC to destabilize the secondary RNA structures and subsequently cooled down to 41ºC to allow primer annealing. Following the addition of the enzymes, the reaction mixtures were incubated at 41ºC for 90 min. Detection of the specific amplification product and internal control was performed using electrochemiluminescent (ECL) beadbased system and the signal measured using the NucliSens Reader (Organon Teknika).
Polymerase chain reaction
DNA extraction of 5 ml EDTA-anticoagulated blood was performed as previously reported 18 using the Qiagen Blood Kit (Qiagen, Hilden, Germany). One hundred nanograms of human DNA was added to the PCR reaction mix and a 147-bp DNA fragment amplified between position 1767 and 1913 of the fourth exon of the immediate-early gene of the HCMV strain AD169 using specific primers. 6 In all assays 0.1, 1, 10 and 100 fg of cloned HCMV-DNA fragment pCM5018 were amplified. Amplicons were detected using the slot blot technique with a digoxigenin-labeled probe specific for HCMV and anti-digoxigenin-antibodies, conjugated with alkaline phosphatase (Roche, Mannheim, Germany). The intensity of the signals of the titration curve was compared with the signal from each clinical sample and a semi-quantitative assessment was performed as recently described. 18 PCR results were available within 1 day.
Quantitative assessment of the viral load in the blood
Quantitative analysis of the HCMV-DNA load was performed in 190 samples using the standardized and commercially available COBAS Amplicor HCMV Monitor Test (Roche Diagnostics, Mannheim, Germany). Nucleic acid was extracted from 0.2 ml EDTA-anticoagulated plasma according to the manufacturer's protocol. Specific primers amplified a 365 bp region of the HCMV DNA polymerase gene. The viral load was assessed by using an external standard and colorimetric amplicon detection. The lower detection limit of the assay was 400 copies/ml plasma. Linearity of the assay was achieved between 400 and 2 ϫ 10 5 copies.
Virus culture
Human foreskin fibroblasts grown in glass tubes were inoculated for 45 min at 37ºC with 0.2 ml of a leukocyte suspension (1-2 ϫ 10 6 cells) prepared by dextran sedimentation. After removal of the clinical material, human foreskin fibroblasts were maintained in culture in MEM at 37ºC. Growth of HCMV was identified by production of its characteristic cytopathic effects on human foreskin fibroblasts. In a separate identically inoculated culture HCMV-specific antigens were detected 48 h after inoculation by an indirect peroxidase technique. Cultures were fixed with cold methanol for 10 min. Monoclonal antibody E13 (Biosoft, Paris, France; dilution 1:750), which is directed against HCMV immediate-early antigen, was added for 60 min at 37ºC. Subsequent incubation with peroxidase-conjugated rabbit anti-mouse Ig antibody (Dako, Hamburg, Germany; dilution 1:750) and with the chromogen aminoethylcarbazol AEC (Sigma, St Louis, MO, USA) yielded brown nuclear staining of infected cells. Cultures were read in a Leitz Fluovert microscope at a 63-fold magnification.
Statistical evaluation
Differences in the time to first HCMV detection and time to first negative result after start of treatment were tested by the Wilcoxon signed rank test. The difference in the viral loads was tested for significance using Student's t-test.
Results
Diagnosis of HCMV infection in patients after allogeneic SCT
All 33 patients included in the study were at risk of developing active HCMV infection according to the pretransplant HCMV serology of the patients and the donors. Of these 33 patients, 19 developed active HCMV infection according to the PCR result from whole blood, and 14 patients remained PCR negative during the whole posttransplant period. According to the results provided by the two assays, patients were divided into three groups: patients with positive DNAemia and NASBA results (n ϭ 16), patients with positive DNAemia but negative results in the NASBA assay (n ϭ 3), and patients with no proof of DNAemia but positive results in the NASBA assay (n ϭ 1) ( Table 2) . 
Detection of HCMV infection
A total of 457 blood samples prospectively collected from 33 patients were analyzed (median 15, range 3-26 samples per patient). Of the 100 blood samples found to be PCRpositive, 47 were also positive by the NASBA assay and three by the viral blood culture method (Table 2) . Sixtyone samples were positive by NASBA, of which 47 were found to be positive by DNA-PCR and two by the blood culture method. Of the three blood samples that tested positive by the culture method, three were PCR positive and two were NASBA positive. All PCR-negative samples were culture negative, and only one NASBA-negative sample was culture positive. All 20 samples analyzed from HCMVseronegative patients transplanted from a seronegative donor were negative by NASBA and PCR. In three PCR-positive patients, the NASBA assay was consistently negative during the entire post-transplant period. Semi-quantitative assessment of the viral loads in the three patients revealed low CMV-DNA levels and none of these patients was found to be culture positive in repetitive blood, urine and throat wash samples. All three patients were found to be PCR positive in two of 14, three of 15 and one of 13 blood samples, respectively, and the two who were treated showed rapid clearance of the viral DNA from the blood upon antiviral treatment for 2 weeks.
One patient was found to be NASBA positive but PCR negative. This patient demonstrated positive culture results in six of 13 urine and five of 13 throat wash samples, clearly indicating viral replication.
Three patients developed HCMV interstitial pneumonia after day 100 post transplantation, all were found to be positive by DNA-PCR and the NASBA assay in multiple blood samples taken prior to the onset of clinical symptoms.
Time to detection of HCMV infection
HCMV infection was diagnosed by PCR at a median of 28 (range 8-82) days post transplantation, by NASBA at a median of 21 (range 4-82) days, and by blood culture at a median of 85 (range 27-143) days post transplantation. In patients screened with both assays from shortly after SCT and having tested positive by both assays, the time to the first positive PCR result was not found to be statistically different (P ϭ 0.44, Wilcoxon signed rank test) (Figure 1) .
Monitoring of antiviral therapy
According to our policy for HCMV-directed preemptive therapy, antiviral treatment was initiated at the time of the second consecutive positive DNA-PCR test result in 18 patients at a median of 35.5 (range 21-88) days post transplantation. At the time of initiation of antiviral therapy, 16 of 18 patients were also found to be NASBA positive (Table 2) . Two patients tested NASBA negative, with a low viral load according to semi-quantitative PCR analysis. In both patients, the viral DNA cleared from the blood within 2 weeks of antiviral therapy. In 12 patients, the efficacy of the antiviral therapy was monitored by both assays. Four of 16 patients who tested positive by both assays were excluded from analysis due to death or lack of sufficient follow-up samples. DNA-PCR and NASBA results became negative after a median of 19 (range 6-43) and 13 (range 2-32) days of antiviral therapy, respectively (P ϭ 0.002, Wilcoxon signed rank test) (Figure 2) . These data indicate a high positive predictive value of the NASBA assay to assess the efficacy of antiviral therapy.
Assessment of the viral load
To further correlate active viral replication as assessed by NASBA and the viral load in the blood, viral load in the plasma was assessed by COBAS Amplicor in 190 randomly selected blood samples included in the study. A positive test result by NASBA and COBAS Amplicor was documented in 32 samples and 26 samples were found to be COBAS positive but NASBA negative. A significantly higher viral load in the plasma was found in PCR + /NASBA + blood samples compared to 
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Discussion
HCMV infection is still a major cause of infection-related morbidity and mortality after allogeneic SCT. With the introduction of antiviral prophylaxis 22 and preemptive antiviral therapy based on sensitive detection methods, the incidence of HCMV disease and HCMV-related mortality early post transplantation has decreased. 5, 8 However, improved management of early HCMV infection until day 100 post transplantation results in a high rate of overtreatment with a possible negative influence on developing anti-HCMV immunity, thereby causing an increased incidence of late HCMV disease occurring after day 100 after stem cell transplantation. 5, 11 In this large prospective study of patients after allogeneic stem cell transplantation, 457 blood samples were tested with the commercialized NucliSens pp67 assay, detecting the UL65-encoded mRNA expressed late during the replication cycle of HCMV, and compared to an in-house HCMV DNA PCR assay, targeting the fourth exon of the immediate-early gene. The results suggest that the NASBA assay could be used safely for preemptive management since none of the assay negative patients developed HCMV disease. In three patients with a short period of HCMVDNAemia and a low viral load according to semi-quantitative assessment, no expression of late HCMV mRNA was detectable. Multiple cultures from blood, urine and throat wash samples revealed negative results and rapid clearance of the viral DNA from the blood was documented in two of three patients receiving antiviral therapy for two positive PCR results within 2 weeks of antiviral therapy.
One patient was detected positive by the NASBA assay but was never found to be HCMV-DNA positive. Secretion of infectious HCMV was demonstrated in repetitive urine and throat wash samples, indicating that negativity of HCMV-DNAemia most likely reflects the limitations of the PCR assay rather than a false positive NASBA result. Thus, despite a few discrepant test results between DNA PCR and pp67 mRNA detection, a high analytical sensitivity and potential clinical relevance of the NASBA assay was demonstrated in high risk patients after allogeneic SCT, as also reported previously by another group. 16 Comparison of the viral loads by COBAS Amplicor between PCR + /NASBA + and PCR + /NASBA Ϫ samples revealed a significantly higher viral load in blood samples tested positive by both assays (P Ͻ 0.01). A recent study in recipients of allogeneic SCT has demonstrated patients with a high viral load to be at an increased risk for subsequent development of HCMV disease. 9 As the dynamics of viral replication might be slow in patients demonstrating no expression of late gene products and a low level of DNAemia, 23 these patients seem to be at a low risk for subsequent onset of HCMV disease. Thus, prospective monitoring of viral replication by the detection of late gene products might help to reduce potentially toxic antiviral treatment in patients at low risk for HCMV disease. Prospective trials will show whether the NASBA assay will allow reduction of overtreatment compared to sensitive PCR-and pp65 antigenemia-based detection methods.
Alternatively, quantitation of the viral DNA load might help to improve the positive predictive value of a positive PCR test result. 14, 24 In solid organ transplant recipients and patients with AIDS, HCMV-related symptoms are associated with a high viral burden in the blood. 25 In recipients of an allogeneic stem cell transplant, the HCMV-DNA load in patients with HCMV disease has been reported to be significantly lower, possibly related to relatively low levels of circulating (infected) leukocytes. Applying sensitive quantitative PCR assays, HCMV-DNA peak titers were higher in symptomatic compared to asymptomatic patients. 25 However, the absolute viral loads in the blood even in patients with HCMV disease show a broad range of variation. This indicates that the assessment of viral replication dynamics by prospective DNA-load monitoring might be more informative in defining the risk for HCMV disease in an individual patient than absolute viral loads at a given time post transplantation. 23 Monitoring of antiviral therapy by PCR and pp65 antigenemia has helped to reduce the duration of antiviral therapy. 7, 8 In this study, monitoring of viral replication by the detection of pp67 late mRNA upon preemptive antiviral therapy allowed for the rapid assessment of the efficacy of antiviral therapy. In comparison to the in-house PCR method, the time to the first negative test result upon antiviral therapy was significantly shorter (P ϭ 0.002) indicating a high predictive value of the NASBA assay to assess the efficacy of antiviral therapy.
In conclusion, the data presented clearly demonstrate a high sensitivity for the NASBA assay to diagnose HCMV infection early and to assess the efficacy of antiviral therapy after allogeneic SCT. A prospective comparison of PCRbased vs NASBA-based HCMV-directed preemptive therapy is ongoing.
